State-of-the-Art Cancer Immunology and Immunotherapy in the USA
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (20 June 2024) | Viewed by 7879
Special Issue Editors
Interests: rare diseases; immunotherapy; precision oncology
Special Issues, Collections and Topics in MDPI journals
Interests: immune checkpoints; checkpoint inhibitors; immunotherapy; tumor immunology; tumor vaccines
Interests: cancer; therapy; signaling pathway; HER; EGF; Wnt; notch; TGF-β; mTOR; PD-1/PD-L1
Special Issues, Collections and Topics in MDPI journals
Interests: developmental therapeutics; molecularly targeted agents; epigenetic modifiers; small molecule inhibitors; immune-oncology; bispecifics; T-cell engagers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer remains the top public health burden worldwide. In the United States, an estimated number of new cancer cases is 1,918,030, and 609,360 estimated deaths cases of cancer in 2022. The leading cause of death is lung cancer, with about 350 losses of lives per day. Immunotherapy of cancer has become an important daily clinical practice of cancer treatment in recent decades. However, the partial response from patients, treatment resistance, metastasis, adverse side effects, and even high cost are remaining major concerns during the therapeutic period. These are the urgent issues that need to be overcome.
The aim of this Special Issue is to collect high-quality basic research, preclinical research, and clinical research on cancer immunology and immunotherapy articles conducted in the United States or by researchers affiliated and/or cooperated with researchers in the United States.
We hope that this Special Issue will highlight state-of-the-art cancer immunology and immunotherapy and promote and raise novel therapeutic strategies against cancer in the USA and worldwide.
Prof. Dr. Razelle Kurzrock
Dr. Anwaar Saeed
Dr. Linlin Guo
Dr. Ludimila Cavalcante
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer research
- immune system
- immunology
- immunotherapy
- CAR T-cell therapy
- checkpoint inhibitor
- monoclonal antibody
- cancer cellular signaling
- tumor microenvironment
- combination therapy